Drugs in R&D obtains ESCI indexing

The open access journal Drugs in R&D was recently included in Clarivate Analytics’ Emerging Sources Citation Index (ESCI). The ESCI only considers journals that are peer reviewed, have ethical publishing practices, meet technical requirements, have English language bibliographic information, and be recommended or requested by a scholarly audience of Web of Science users.

The ESCI was launched in 2015 and citations from the ESCI will be included in the citation counts for the Journal Citation Reports that contribute to the Impact Factors of other journals. Journals in the ESCI will be discoverable via the Web of Science with an identical indexing process to other indexed journals, including citation counts and author information. Articles in ESCI indexed journals will also be included in an author’s H-Index calculation and analyses conducted with Web of Science data and related products such as InCites.

Inclusion in ESCI will improve the visibility of a journal and provides a mark of quality which should encourage submissions from authors

Delafloxacin (Baxdela™): First Global Approval – Flexible dosing, broad spectrum coverage, effective against resistant pathogens – appealing characteristics for the treatment of ABSSSI

Delafloxacin (Baxdela™): First Global Approval – Flexible dosing, broad spectrum coverage, effective against resistant pathogens – appealing characteristics for the treatment of ABSSSI

The recent first global approval of delafloxacin has been reviewed in detail in the First Global Approval report in Adis journal Drugs[1], based on the development milestones tracked in AdisInsight.[2] Continue reading “Delafloxacin (Baxdela™): First Global Approval – Flexible dosing, broad spectrum coverage, effective against resistant pathogens – appealing characteristics for the treatment of ABSSSI”

New health economics book gets airtime

New health economics book gets airtime

Professor Simon Eckermann recently launched his book Health Economics from Theory to Practice: Optimally Informing Joint Decisions of Research, Reimbursement and Regulation with Health System Budget Constraints and Community Objectives. Now, a related interview with Professor Eckermann has been broadcast on National Radio’s Health Report. This reflects the fact that, although it is a high-level academic book aimed at specialist audiences, the application of health economics is relevant to the general population. The book provides a robust set of health economic principles and methods to inform societal decisions in relation to research, reimbursement and regulation (pricing and monitoring of performance in practice). The recent launch of the book involved a public policy lecture entitled “Successful baby boomer ageing with budget constraints: where should baby boomer ageing be heading”.

Durvalumab (Imfinzi™): First Global Approval – Empower the host – disarm the disease; immune-stimulation brings hope in bladder cancer

Durvalumab (Imfinzi™): First Global Approval – Empower the host – disarm the disease;  immune-stimulation brings hope in bladder cancer

The recent first global approval of durvalumab has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[1] based on the development milestones tracked in AdisInsight.[2] Continue reading “Durvalumab (Imfinzi™): First Global Approval – Empower the host – disarm the disease; immune-stimulation brings hope in bladder cancer”